龙启生物制药（immumowake）是一家致力于开发和商业化肿瘤治疗的新型双特异抗体的全球Biotech公司，专注于抗体激活机体免疫、改善肿瘤微环境，治疗实体肿瘤的领域。龙启的目标是开发真正能与西方大药企匹敌的重磅炸弹药物，解决临床未满足的需求。公司目前已完成A轮融资，美国的研发中心位于伯明翰，中国研发中心位于上海张江药谷，后期上海将发展成为龙启制药的全球研发中心。
龙启制药的创始人吴晓云博士是资深的肿瘤免疫治疗领域专家、连续创业者。吴博士在美国工作学习三十多年，是一位兼具学术背景、创业经验并乐于分享的优秀创业者。2021年底，吴博士带领核心团队和研发成果以及技术平台回到中国，开启中国肿瘤药出海的新征程。现阶段两个免疫治疗双抗药物正在积极准备IND申报的资料，预计明年进行中美双报。希望通过龙启人的携手努力，为中国新药国际化添砖加瓦！
Introduction of Immunowake Biopharmaceutical Co., Ltd
Immunowake is a global biotech company committed to developing and commercializing new bispecific antibodies for tumor treatment. It focuses on the field of antibody activating body immunity, improving tumor microenvironment and treating solid tumors. Immunowake's goal is to develop blockbuster drugs that can truly compete with major Western pharmaceutical companies to solve the unmet clinical needs. At present, the company has completed Round A financing. The R & D center in the United States is located in Birmingham, and the R & D center in China is located in Shanghai Zhangjiang Pharmaceutical Valley. Meanwhile, Shanghai will develop into the global R & D center of Immunowake biopharmaceutical.
Dr. Xiaoyun Wu , the founder of Immunowake pharmaceutical, is a senior expert and continuous entrepreneur in the field of tumor immunotherapy. Dr. Wu has worked and studied in the United States for more than 30 years. He is an excellent entrepreneur who has both academic background and entrepreneurial experience. At the end of 2021, Dr. Wu led the core team, R & D achievements and technical platform back to China, opening a new journey of Chinese cancer drugs to international market. At this stage, the two immunotherapeutic Bispecific antibodies actively preparing the data of IND declaration, and it is expected that the Sino-US double declaration will be carried out next year. We hope to contribute to the internationalization of Chinese new drugs through the joint efforts of Immunowake Scientists!